These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 33461918)
41. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience. Fabricius MM; Dandachi D Mo Med; 2021; 118(1):74-80. PubMed ID: 33551490 [TBL] [Abstract][Full Text] [Related]
42. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19). Gupta P Indian J Tuberc; 2021 Jan; 68(1):92-98. PubMed ID: 33641858 [TBL] [Abstract][Full Text] [Related]
43. Passive immunization and its rebirth in the era of the COVID-19 pandemic. Pavia CS; Wormser GP Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975 [TBL] [Abstract][Full Text] [Related]
44. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696 [TBL] [Abstract][Full Text] [Related]
45. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691 [TBL] [Abstract][Full Text] [Related]
46. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19. Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925 [No Abstract] [Full Text] [Related]
47. [Is convalescent plasma an alternative treatment for Covid-19 patients?]. Trejo-Gómor JE; Dimas-González J; Lagunas-Martínez A Salud Publica Mex; 2020; 62(6):870-871. PubMed ID: 33620985 [No Abstract] [Full Text] [Related]
48. An overview of Covid-19 pandemic: immunology and pharmacology. Arif A; Ansari S; Ahsan H; Mahmood R; Khan FH J Immunoassay Immunochem; 2021 Sep; 42(5):493-512. PubMed ID: 33788668 [TBL] [Abstract][Full Text] [Related]
49. Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey study. Masser BM; Ferguson E; Thorpe R; Lawrence C; Davison TE; Hoad V; Gosbell IB Transfus Med; 2021 Jun; 31(3):176-185. PubMed ID: 33368777 [TBL] [Abstract][Full Text] [Related]
50. Use of Convalescent Plasma in the Management of COVID-19. Dandachi D; Khalaf SA Mo Med; 2021; 118(2):118. PubMed ID: 33840851 [No Abstract] [Full Text] [Related]
51. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
52. Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry. Turecek PL; Hibbett D; Kreil TR Vox Sang; 2022 Jun; 117(6):780-788. PubMed ID: 35298841 [TBL] [Abstract][Full Text] [Related]
53. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O Front Public Health; 2022; 10():816848. PubMed ID: 35372242 [TBL] [Abstract][Full Text] [Related]